Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its independent Data Monitoring Committee (DMC) has completed review of an interim analysis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE